Acute hemodynamic response to single oral doses of BAY 60-4552, a soluble guanylate cyclase stimulator, in patients with biventricular heart failure

類似資料

• Warfarin pharmacodynamics and pharmacokinetics are not affected by the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
  著者:: Frey, Reiner, 等
  出版事項: (2009)
• Effects of age and sex on the pharmacokinetics of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
  著者:: Frey, Reiner, 等
  出版事項: (2016)
• Assessment of the effects of renal impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
  著者:: Frey, Reiner, 等
  出版事項: (2016)
• Assessment of the effects of hepatic impairment and smoking on the pharmacokinetics of a single oral dose of the soluble guanylate cyclase stimulator riociguat (BAY 63-2521)
  著者:: Frey, Reiner, 等
  出版事項: (2016)
• Antiplatelet effects of aspirin are not affected by the soluble guanylate cyclase activator cinaciguat (BAY 58-2667)
  著者:: Frey, Reiner, 等
  出版事項: (2011)